Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MCSE vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: MCSE 1 – 5 ACAD Matrix Metrics: MCSE 3 – 7 ACAD

As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over Franklin Templeton ETF Trust Franklin Sustainable International Equity ETF (MCSE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MCSE carries a Unified Composite Score of 53.9/100 (HOLD) at $13.82 (N/M Forward P/E, N/A operating margin), whereas ACAD carries 42.1/100 (HOLD) at $18.67 (17.0x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While MCSE currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. ACAD 42.1/100 HOLD), ACAD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+22.8% vs. N/A YoY).
  • Technical & Structure Timing Caution: MCSE is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MCSE vs ACAD
MCSE NASDAQ
Franklin Templeton ETF Trust Franklin Sustainable International Equity ETF
Institutional Equity
$13.82
-0.07% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.87β · 18% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 45.0 Fund 44.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.6%) with fading momentum, RSI 46
RSI-14: 46.4 · SMA20: $13.93 · SMA50: $14.06
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$18.67
-0.43% 1D
Market Cap $3.2B
TTM Revenue $1.20B
Forward P/E 17.0x
Beta / 30D Vol 0.13β · 92% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 43.0 Fund 53.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $19.82 · SMA50: $21.61

6-Pillar Scorecard Institutional Category Breakdown (MCSE 1 – 5 ACAD)

Columns: Metric · MCSE · ACAD
1. Valuation Multiples ACAD
Forward P/E N/M 17.0x
Trailing P/E N/M 8.8x
PEG Ratio N/M N/M
EV / Revenue N/M 2.5x
2. Growth & Scale ACAD
Revenue Growth (YoY) N/A +22.8%
Earnings Growth (YoY) N/A -26.2%
TTM Revenue (USD) N/A $1.20B
Market Cap N/A $3.2B
3. Profitability & Quality ACAD
Gross Margin N/A 63.9%
Operating Margin N/A 10.2%
Net Profit Margin N/A 30.1%
Return on Equity (ROE) N/A 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) N/A $181M
Cash Flow Margin N/A 15.0%
Net Cash / Leverage N/A ROE $251M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MCSE
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 119.0% (20th %ile)
Put/Call OI Skew N/A 0.33x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity N/A 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MCSE (3) vs ACAD (7)
Institutional Metric MCSE ACAD Criterion Row Edge
Market Capitalization
Scale
N/A $3.2B Larger Scale ACAD
Trailing P/E Ratio
Valuation
N/M 8.8x Lower Multiple ACAD
Forward P/E Ratio
Valuation
N/M 17.0x Lower Multiple ACAD
Revenue Growth (YoY)
Growth
N/A +22.8% Higher Growth ACAD
Operating Margin (TTM)
Profitability
N/A 10.2% Higher Margin ACAD
Net Profit Margin
Profitability
N/A 30.1% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
N/A 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
63% ($12–$15) 19% ($16–$31) Stronger Trend MCSE
Beta / 30D Volatility
Risk Regime
0.87β · 18% Vol 0.13β · 92% Vol Lower Realized Risk MCSE
Unified Institutional Score
Composite Signal
53.9 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite MCSE
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACAD +12.0 pp
MCSE: +2.22% · ACAD: +14.22%
3M Horizon ACAD +15.4 pp
MCSE: -1.57% · ACAD: +13.83%
6M Horizon ACAD +15.4 pp
MCSE: -1.57% · ACAD: +13.83%
1Y Horizon ACAD +15.4 pp
MCSE: -1.57% · ACAD: +13.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MCSE vs ACAD. Trailing 12-month operating profitability (MCSE N/A vs ACAD 10.2%) and valuation multiples (MCSE N/M vs ACAD 17.0x Forward P/E) are benchmarked directly in Pillar 4 below.

MCSE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ACAD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.20B
Gross Margin63.9%
Op. Margin10.2%
ROE / Fwd P/E31.4% · 17.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MCSE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MCSE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 119.0%
IV Percentile 20th %ile
Put/Call OI Skew 0.33x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MCSE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ MCSE vs ACAD Key Questions & Quantitative Answers

As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over Franklin Templeton ETF Trust Franklin Sustainable International Equity ETF (MCSE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MCSE carries a Unified Composite Score of 53.9/100 (HOLD) at $13.82 (N/M Forward P/E, N/A operating margin), whereas ACAD carries 42.1/100 (HOLD) at $18.67 (17.0x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While MCSE currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. ACAD 42.1/100 HOLD), ACAD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+22.8% vs. N/A YoY). Technical & Structure Timing Caution: MCSE is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: MCSE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, MCSE generates N/A in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, MCSE deploys N/A (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

ACAD screens cheaper on headline valuation multiples. MCSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACAD trades at 17.0x Forward P/E, 8.8x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MCSE (N/A ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MCSE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 18% Vol realized risk). By comparison, ACAD carries 119.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.13β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Franklin Templeton ETF Trust Franklin Sustainable International Equity ETF (MCSE) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.